Table III.
Results evaluated by the GRADE system.
| A, Cardiac events, target lesion revascularization and thromobosis | |||||
|---|---|---|---|---|---|
|
| |||||
| Outcomes | Comparative risksa (95% CI) | Relative effect (95% CI) | No. of participants (no. of studies) | Quality of evidence (GRADE) | |
|
| |||||
| Assumed risk PPS per 1000 | Corresponding risk BPS per 1000 | ||||
| Major adverse cardiac events at one-year follow-upa | OR 1.05 (0.93–1.18) | 15938 (11) | ++++ (high) | ||
| Study population | 76 | 80 (71–89) | |||
| Moderate | 63 | 66 (58–74) | |||
| Target lesion revascularization at one-year follow-upb | OR 0.98 (0.84–1.15) | 14263 (10) | +++− (moderate) | ||
| Study population | 47 | 46 (39–53) | |||
| Moderate | 40 | 39 (34–46) | |||
| Definite or portable stent thrombosis at one-year follow-upb | OR 1.03 (0.73–1.46) | 15818 (10) | +++− (moderate) | ||
| Study population | 8 | 8 (6–12) | |||
| Moderate | 3 | 3 (2–4) | |||
| Major adverse cardiac events at long term follow-upc | OR 0.89 (0.78–1.02) | 5376 (4) | ++++ (high) | ||
| Study population | 143 | 128 (112–146) | |||
| Moderate | 127 | 113 (99–130) | |||
| Target lesion revascularization at long term follow-upd | OR 0.92 (0.78–1.07) | 5376 (4) | ++++ (high) | ||
| Study population | 110 | 101 | (86–118) | ||
| Moderate | 107 | 98 | (83–114) | ||
| Definite stent or portable thrombosis at long term follow-upc | OR 0.72 (0.51–1.04) | 5396 (4) | ++++ (high) | ||
| Study population | 27 | 20 (14–28) | |||
| Moderate | 17 | 12 (9–18) | |||
|
| |||||
| B, Late lumen loss and stenosis | |||||
|
| |||||
| Outcomes | Absolute difference in outcome | No. of participants | Quality of evidence (GRADE) | ||
|
| |||||
| Late lumen loss in stent (mm)e | Mean late lumen loss in stent in the intervention groups was 0.04 (0.08–0.00) lower | 5173 (8) | ++−− (low) | ||
| Stenosis of lumen diameter in stent (%)e | Mean stenosis of lumen diameter in stent in the intervention groups was 1.43 lower (3.02 lower to 0.17 higher) | 5183 (8) | ++−− (low) | ||
The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
a
follow-up of 12 months;
b–e
mean follow-ups of b12, c36, d33 and e8 months;
CI, confidence interval; OR, odds ratio; GRADE, GRADEPro software (Cochrane Informatics and Knowledge Managment, London, UK). PPS, permanent polymer stent; BPS, biodegradable polymer stent.